CFRA sets a price target of $126 for Novartis, indicating a potential increase of about 2.16$123.12, with a market capitalization of approximately $240.22 billion.Novartis (NYSE:NVS) is a global healthcare company based in Switzerland, known for its innovative medicines and treatments. It operates in various segments, including pharmaceutica ...